OSU Navigation Bar

The Ohio State University University Libraries Knowledge Bank

Administration of a Glycoprotein IIb/IIIa Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia

Please use this identifier to cite or link to this item: http://hdl.handle.net/1811/31906

Show full item record

Files Size Format View
V105N4_74.pdf 30.11Kb PDF View/Open

Title: Administration of a Glycoprotein IIb/IIIa Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia
Creators: Silver, Kevin H.; Newman, Isadore; Rohr, Susan M.; Johnson, Jeremy; Josephson, Richard A.
Issue Date: 2005-09
Citation: The Ohio Journal of Science, v105, n4 (September, 2005), 74-78.
Abstract: The combination of aspirin, a thienopyridine derivative, and a glycoprotein IIb/IIIa receptor inhibitor has become standard therapy for patients undergoing percutaneous coronary intervention (PCI). Recent studies have shown an increased incidence of thrombocytopenia in those patients receiving a high loading dose of clopidogrel (thienopyridine) with abciximab (IIb/IIIa receptor inhibitor) prior to coronary intervention. We reviewed the records of 504 patients who underwent PCI at a large tertiary care hospital and noted an incidence of thrombocytopenia of 4.8%, comparable to published historical controls who received abciximab without clopidogrel. In patients undergoing PCI, there was no difference in thrombocytopenia or bleeding complications between patients receiving a high or a low dose of a thienopyridine. We conclude that a high loading dose of a thienopyridine derivative prior to PCI may be administered safely and efficaciously in the setting of concomitant administration of abciximab without an undue risk of thrombocytopenia.
URI: http://hdl.handle.net/1811/31906
ISSN: 0030-0950
Rights: Reproduction of articles for non-commercial educational or research use granted without request if credit to The Ohio State University and The Ohio Academy of Science is given.
Bookmark and Share